Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Stefanie Brackin

Nurse Practitioner, Family Jonesboro, AR Nurse Practitioner

NPI 1225512635 CMS profile 11138297

1812 Pleasant Grove Rd Ste B, Jonesboro, AR 72405

Open in the dashboard

General payments

$50,681

530 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Stefanie Brackin of Jonesboro, AR is reported in the CMS Open Payments database as having received $50,681 across 530 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $22 1
2024 General $13,040 147
2023 General $11,956 168
2022 General $25,663 214

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stefanie Brackin
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Stefanie Brackin were reported at $22. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Stefanie Brackin Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $0 $124 $35–$379 $132
2022 $25,663 $141 $44–$430 $149
2023 $11,956 $154 $49–$476 $160
2024 $13,040 $165 $51–$504 $164
2025 $22 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. AbbVie, Inc. $43,245 147 payments
  2. Novartis Pharmaceuticals Corporation $778 49 payments
  3. EMD Serono, Inc. $738 29 payments
  4. Alexion Pharmaceuticals, Inc. $706 26 payments
  5. SK Life Science, Inc. $679 28 payments
  6. Biogen, Inc. $641 32 payments
  7. Amgen Inc. $407 22 payments
  8. US WorldMeds, LLC $405 14 payments
  9. Pfizer Inc. $362 38 payments
  10. Lundbeck LLC $348 21 payments
  11. Other $2,371 124 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $40,533 26 payments
  2. Food and Beverage $9,661 493 payments
  3. Travel and Lodging $487 11 payments
Products named General payments · program years 2022–2025
  1. UBRELVY $28,748 76 payments
  2. QULIPTA $23,118 58 payments
  3. ULTOMIRIS $684 25 payments
  4. KESIMPTA $552 34 payments
  5. BOTOX Neuroscience $442 24 payments
  6. AIMOVIG $407 22 payments
  7. BOTOX Botox Therapeutic $385 19 payments
  8. VUMERITY $382 22 payments
  9. NURTEC ODT $362 38 payments
  10. ZAVZPRET $301 32 payments
  11. Other $5,033 258 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 59 drugs

Part D claims

4,045

Median for Nurse Practitioner: 389

Drug cost

$979,130

Median for Nurse Practitioner: $21,885

Branded share of claims

24.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ubrelvy Ubrogepant Brand 200 $250,512
Kesimpta Pen Ofatumumab Brand 15 $153,254
Aimovig Autoinjector Erenumab-Aooe Brand 159 $142,507
Avonex Pen (4 Pack) Interferon Beta-1a Brand 12 $95,034
Qulipta Atogepant Brand 48 $58,341
Nurtec Odt Rimegepant Sulfate Brand 44 $48,538
Emgality Pen Galcanezumab-Gnlm Brand 59 $46,115
Xcopri Cenobamate Brand 30 $33,595
Emgality Syringe Galcanezumab-Gnlm Brand 26 $31,479
Ajovy Autoinjector Fremanezumab-Vfrm Brand 23 $16,551

The 10 drugs with the highest cost, of 59 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$65,885

Of which drugs: $30,310

Medicare patients

277

Average age 71

Services billed

3,668

186 women, 91 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 60%
Depression 42%
Diabetes 36%
Ischemic heart disease 29%
Chronic kidney disease 26%
Heart failure 23%
COPD 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 34 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QULIPTA
  • AbbVie, Inc. $10,225
$10,225 48 —
ULTOMIRIS
  • Alexion Pharmaceuticals, Inc. $324
$324 — —
BOTOX
  • AbbVie, Inc. $269
$269 — —
KESIMPTA
  • Novartis Pharmaceuticals Corporation $207
$207 15 —
Apokyn
  • US WorldMeds, LLC $195
$195 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 34 with Patron

Records

530 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record